Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00004218




Registration number
NCT00004218
Ethics application status
Date submitted
28/01/2000
Date registered
27/01/2003
Date last updated
18/12/2013

Titles & IDs
Public title
Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
Scientific title
Chronic Lymphocytic Leukemia Trial 4: A Randomized Comparison of Chlorambucil, Fludarabine and Fludarabine Plus Cyclophosphamide
Secondary ID [1] 0 0
LRF-CLL4
Secondary ID [2] 0 0
CDR0000067454
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Leukemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Outcomes

Eligibility
Key inclusion criteria
DISEASE CHARACTERISTICS:

* Diagnosis of B-cell chronic lymphocytic leukemia (CLL) requiring therapy and meeting the following criteria:

* Previously untreated disease
* Peripheral blood morphology, excluding other leukemia and low-grade lymphoma in leukemic phase
* Cell markers: CD5+, CD23+, SmIg (weak), CD79b-, FMC7-
* Persistent lymphocytosis (greater than 10,000/mm^3)
* At least 40% bone marrow infiltration
* Stage 0 or I progressive disease indicated by at least one of the following:

* Persistent rise in lymphocyte count with doubling time less than 12 months
* Downward trend in hemoglobin and/or platelet count
* At least 50% increase in size of liver and/or spleen and/or lymph nodes
* Appearance of lymphadenopathy, hepatomegaly, or splenomegaly
* Constitutional symptoms caused by disease

* Pyrexia
* Night sweats
* Weight loss OR
* Stage II or III

PATIENT CHARACTERISTICS:

Age:

* Not specified

Performance status:

* Not specified

Life expectancy:

* Not specified

Hematopoietic:

* See Disease Characteristics

Hepatic:

* Bilirubin no greater than 2 times upper limit of normal (ULN)*
* SGOT/SGPT no greater than 2 times ULN* NOTE: * Unless due to CLL

Renal:

* Creatinine clearance at least 30 mL/min

Other:

* No other cancer or life-threatening disease
* Not pregnant
* Fertile patients must use effective contraception during and for 6 months after study therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* Not specified

Endocrine therapy

* No concurrent corticosteroids (e.g., dexamethasone) as antiemetics

Radiotherapy

* Not specified

Surgery

* Not specified
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/1999
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2007
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Croatia
State/province [2] 0 0
Zagreb
Country [3] 0 0
Greece
State/province [3] 0 0
Ioannina
Country [4] 0 0
Greece
State/province [4] 0 0
Rio Patras
Country [5] 0 0
Ireland
State/province [5] 0 0
Dublin
Country [6] 0 0
Ireland
State/province [6] 0 0
Galway
Country [7] 0 0
Italy
State/province [7] 0 0
Bergamo
Country [8] 0 0
New Zealand
State/province [8] 0 0
Christchurch
Country [9] 0 0
Russian Federation
State/province [9] 0 0
Moscow
Country [10] 0 0
United Kingdom
State/province [10] 0 0
England
Country [11] 0 0
United Kingdom
State/province [11] 0 0
Northern Ireland
Country [12] 0 0
United Kingdom
State/province [12] 0 0
Scotland
Country [13] 0 0
United Kingdom
State/province [13] 0 0
Wales

Funding & Sponsors
Primary sponsor type
Other
Name
Leukemia Research Fund
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
Medical Research Council
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Daniel Catovsky, MD
Address 0 0
Royal Marsden NHS Foundation Trust
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents


Results not provided in https://clinicaltrials.gov/study/NCT00004218